1. Generics Bulletin
  2. >>Business

Goldman Ends Endo Coverage Following Q2 EBITDA Guide

NY-Based Investment Bank Halves Its 2023 Vasostrict Sales Guide

 
• By Dean Rudge

One of the largest investment banks in the US has cancelled its coverage of Endo after the US-based firm revealed the extent of generic competition to its lucrative Vasostrict brand.

Endo shares had been 'sent reeling' • Source: 360b/Shutterstock

Goldman Sachs is to cease coverage of struggling Endo International plc. The move follows the US-based firm guiding for its adjusted EBITDA to fall by as much as 65% quarter-over-quarter in the wake of generic competition to its $900m Vasostrict (vasopressin) injectable.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Generics Bulletin

Tevogen Launches Generics-Focused Initiative As Trump Eyes Pharma Tariffs

 
• By Adam Zamecnik

As the Trump Administration continues to send ripples across industries, Tevogen has launched a new generic drugs-focused endeavor that plans to reshore production to the US.

Coherus Marks Exit From Biosimilars By Completing Udenyca Divestment

 
• By Dave Wallace

Coherus has officially marked its exit from biosimilars by completing the divestment of its Udenyca pegfilgrastim franchise. Meanwhile, buyer Accord BioPharma has set out how it expects to benefit not only from a growing asset but also from the Coherus personnel that have moved over.

Sandoz Admits To Widescale Infringement In Resolving US Rinvoq Patent Tussle

 
• By Dean Rudge

Sandoz has reached an agreement with AbbVie to dismiss without prejudice patent-infringement litigation involving more than 20 patents shielding the originator’s blockbuster JAK inhibitor Rinvoq.